Russell 2000 Falls 1.66% as Mobility Global Rises 16%: What the 8-K Says
While U.S. small caps fell, Mobility Global rose 16.11% on a third-quarter earnings 8-K. Chagee rose 9.57% on a reported special dividend and Belite Bio 8.99% on reported results and an FDA date; neither one's filing content is confirmed.

Published Nov. 13 KST. Prices are Nov. 12 U.S. regular-session closes.

Seoul — U.S. stocks fell on Nov. 12: the S&P 500 lost 0.35%, the Nasdaq Composite 0.39% and the Russell 2000, an index of 2,000 smaller U.S. companies, 1.66%. Mobility Global (MBGL) still rose 16.11%, and the reason is confirmed by its third-quarter earnings 8-K filed with the SEC. Chagee (CHA) rose 9.57% on a reported special dividend, and Belite Bio (BLTE) rose 8.99% on reported results and an FDA date. Each of those two had one 6-K filing that day, but its content is not confirmed, so the reasons rest on news reports.
This article covers three stocks that closed up 8.99% or more in the regular session. One has its reason confirmed by a company filing, and two are explained by news reports only.
At a glance
| Stock (ticker) | Close, move, dollar volume | Why it rose | Nature | Evidence | Overheating | What to check next |
|---|---|---|---|---|---|---|
| Mobility Global (MBGL) | $23.13, +16.11%, $168.5M | Q3 results and 2026 guidance | Substance, one-off | Filing confirmed | 1/4, caution | Guidance figures in the 8-K exhibit; what the same-day S-4 covers |
| Chagee (CHA) | $13.51, +9.57%, $32.9M | About $1.95 special dividend and a three-year payout policy | Substance, one-off | Reports only | 0/4, normal | Record and payment dates; the 6-K text |
| Belite Bio (BLTE) | $169.96, +8.99%, $84.2M | Q3 results and tinlarebant FDA timing | Expectation | Reports only | 0/4, normal | FDA decision date; next-quarter loss |
Dollar volume is for the regular session. After-hours prices are not used.
Mobility Global rose 16% on third-quarter results

Mobility Global rose 16.11% to $23.13 on the day it reported third-quarter results. According to an 8-K (a current report to the SEC) filed Nov. 12, the company issued an earnings release covering the quarter ended Sept. 30, 2026 and certain 2026 guidance. The items are 2.02 (results) and 9.01 (exhibits). A 10-Q (quarterly report) and an S-4 were filed the same day.
News reports point the same way. Seeking Alpha said the stock jumped on a Q3 beat and a higher EBITDA outlook, and Investing.com cited raised profit guidance. But the 8-K text only says guidance was provided, not that it was raised, so the raise rests on reports. From Oct. 9 through Nov. 11 the stock closed between $17.84 and $19.93, then moved out of that range in one session. It is up 26.9% from its Oct. 9 close.
The fundamentals are ordinary next to the move. It passed three of four checks (profitable, debt, revenue growth) and missed the PER-of-25-or-less test, so 3/4. PER is 53.8 and revenue growth in our check is 6.6%, a figure with its own basis that may differ from the quarter's reported numbers. An S-4 is a registration form used when issuing securities in a merger or similar deal. The title alone does not reveal the counterparty or size, so we treat it as neutral and the earnings 8-K as positive. All filings in the past seven days came on Nov. 12.
Overheating check: 1 of 4 signals. RSI(14) is 83.5, above 80. The stock is 19.8% above its 20-day average, volume is 2.0 times normal and the 5-day move is +16.5%, none of which reach their thresholds. The close sits at 100% of the 52-week range, the 52-week high.
Filings and reports reviewed - Nov. 12, 8-K (2.02, 9.01), Q3 results: https://www.sec.gov/Archives/edgar/data/2090312/000209031226000034/mbgl-20261112.htm - Nov. 12, S-4: https://www.sec.gov/Archives/edgar/data/2090312/000110465926126248/mbgl-20260930xs4.htm - Nov. 12, 10-Q: https://www.sec.gov/Archives/edgar/data/2090312/000209031226000035/mbgl-20260930.htm - Nov. 13, Seeking Alpha, Mobility Global jumps 12% on Q3 beat, higher EBITDA outlook
Whether the gain lasts depends on Exhibit 99.1 of the 8-K: did 2026 guidance actually rise, and does the quarter include one-time gains? Once the purpose of the S-4 is known, it will show whether another driver sits behind the move.
Chagee rose 9.6% on a special dividend (the filing's content is unconfirmed)

Chagee rose 9.57% to $13.51 on a special dividend and a three-year payout policy. Per Benzinga, the board declared a special cash dividend of about $1.95 per share or ADS and approved a policy of paying at least 50% of net income, starting with the fiscal year ending Dec. 31, 2027. Stock Titan reported the same, and Investing.com said Jefferies reiterated its rating on dividend yield.
One 6-K (a current report foreign issuers file) was filed that day, but its text is not confirmed, so we cannot say whether it carries the dividend amount or dates. The evidence is therefore reports only. That 6-K is the only filing in the past seven days. Against the $13.51 close the dividend is about 14%, and against the prior close of $12.33 about 16%. The special dividend is a one-time payment; the lasting piece is the 50%-of-net-income policy.
Overheating check: 0 of 4 signals. Volume was 3.7 times normal, but RSI is 63.8, the gap to the 20-day average is +8.6% and the 5-day move is +10.0%. The stock is 21.1% above its 200-day average, at 61% of its 52-week range (16.8% below the high). It passed all six fundamental checks, 6/6, with PER at 13.6. Revenue growth in the check is 2.5%.
Filings and reports reviewed - Nov. 12, 6-K (content unconfirmed): https://www.sec.gov/Archives/edgar/data/2013649/000110465926125793/tm2629555d1_6k.htm - Nov. 12, Benzinga, Chagee Declares Special Cash Dividend Of ~$1.95/Share Or ADS - Nov. 12, Seeking Alpha, Chagee rallies after announcing a special dividend and setting a three-year dividend policy
The record and payment dates decide what comes next, because the price can adjust when the payout leaves the company. The 6-K text should also show whether its dividend amount matches the reported $1.95.
Belite Bio rose 9% on results and an FDA date (losses are not shrinking)

Belite Bio rose 8.99% to $169.96 after third-quarter results and reports on the FDA timing for tinlarebant. Per Benzinga, the loss per share was $0.65 against an estimate of a $0.80 loss, while MarketScreener said the adjusted loss widened. So the stock did not rise on lower losses; it was a smaller loss than expected, and liquidity may have helped. Mugglehead reported $774M in liquidity ahead of the FDA date, about 11% of the roughly $6.8B market cap.
One 6-K was filed that day, but its content is not confirmed; it is the only filing in the past seven days. On Nov. 10 Simply Wall St asked whether priority FDA review changes the investment case, so the FDA process was already in the market's view before today. The driver looks more like expectation of approval than the earnings figures.
Overheating check: 0 of 4 signals. The 5-day move is +18.7%, volume 3.1 times normal and RSI 68.6. The stock is 6.1% above its 200-day average and at 72% of its 52-week range (12.2% below the high). It passed none of the three fundamental checks (profit, ROE, PER), so 0/3.
Filings and reports reviewed - Nov. 12, 6-K (content unconfirmed): https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_6k.htm - Nov. 12, Benzinga, Belite Bio Q3 EPS $(0.65) Beats $(0.80) Estimate - Nov. 12, Mugglehead, Belite Bio reports US$774M in liquidity ahead of tinlarebant FDA date
What matters next is when the FDA decides and which way it goes, since a price lifted by approval hopes has nothing to cushion a miss. The next quarter's loss against the $774M in liquidity is the other number to read.
FAQ
Why did they rise? Mobility Global on Q3 results and 2026 guidance, Chagee on a special dividend and payout policy, and Belite Bio on results and reported FDA timing.
Which filing is the evidence? For Mobility Global, the Nov. 12 8-K (items 2.02, 9.01). Chagee and Belite Bio each have a 6-K whose content is unconfirmed, so news reports are the basis.
What should I check next? Chagee's record and payment dates, Belite Bio's FDA decision date, and for Mobility Global the S-4's purpose and the guidance figures.
What happened to the stocks we covered before
Moves are from each article's date to the Nov. 12 close, so the periods differ.
| Stock | Verdict then | Article date | Move since |
|---|---|---|---|
| Firefly Aerospace Inc. (FLY) | Reports | Nov. 7 | +21.9% |
| AppLovin Corporation (APP) | Earnings | Nov. 6 | +10.6% |
| JFrog Ltd. (FROG) | Earnings | Nov. 7 | +9.5% |
| AAON | Filing | Nov. 11 | +5.1% |
| Acadia Pharmaceuticals (ACAD) | Reports | Nov. 11 | -0.8% |
| Csquare (CSQR) | Earnings | Nov. 11 | -1.7% |
| Karman Holdings Inc. (KRMN) | Earnings | Nov. 7 | -11.2% |
| Encore Capital Group, Inc. (ECPG) | Earnings | Nov. 6 | -12.9% |
Of the five earnings-driven names, AppLovin and JFrog kept rising while Karman and Encore fell more than 10%, so the same verdict led to different paths. Among reports-only names, Firefly rose 21.9% and Acadia slipped slightly.
FAQ
Why did Mobility Global stock go up?
$23.13, +16.11%, $168.5M. Evidence: Substance, one-off. What to check next: Filing confirmed.
Why did Chagee stock go up?
$13.51, +9.57%, $32.9M. Evidence: Substance, one-off. What to check next: Reports only.
Why did Belite Bio stock go up?
$169.96, +8.99%, $84.2M. Evidence: Expectation. What to check next: Reports only.